A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of MabThera in patients with active
rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with
methotrexate. Eligible patients will receive MabThera (1000mg by intravenous infusion) on
days 1 and 15, and background methotrexate (oral or subcutaneous dose of 10-25mg weekly).
After the initial study period of 24 weeks, eligible patients may receive up to 3
re-treatments with MabThera. The anticipated time on study treatment is 1-2 years, and the
target sample size is <100 individuals.